Lung Cancer Drug Study: Summit Results
- Summit Therapeutics announced Friday that its PD1-VEGF antibody, ivonescimab, met the primary endpoint in a Phase 3 clinical trial.
- However, the study has not yet confirmed an overall survival benefit for patients treated with ivonescimab.
- Following the announcement, Summit shares experienced a important decline, falling by 30%.
Summit Therapeutics’ ivonescimab shows promise, delaying lung cancer progression in a Phase 3 trial, a key takeaway from the recent Summit Results. While the drug successfully met its primary endpoint, the study has yet too definitively prove an overall survival benefit for patients. This advancement has sent shares plummeting by 30%, signaling significant investor concern about the long-term commercial viability of this potential lung cancer treatment. The news, reported here at News Directory 3, highlights the critical importance of demonstrating survival benefits in securing FDA approval and realizing the full potential of ivonescimab as a cancer immunotherapy.The company is closely monitoring the trial data. Discover what’s next for this groundbreaking immunotherapy and its impact on the fight against lung cancer.
Summit therapeutics’ Ivonescimab Delays lung Cancer Progression
Updated June 01, 2025
Summit Therapeutics announced Friday that its PD1-VEGF antibody, ivonescimab, met the primary endpoint in a Phase 3 clinical trial. The drug delayed the progression of lung cancer in patients from the U.S. and other western countries, mirroring earlier results from trials conducted in China.
However, the study has not yet confirmed an overall survival benefit for patients treated with ivonescimab. This lack of demonstrated survival enhancement could impact the company’s ability to secure FDA approval and realize the drug’s potential as a blockbuster lung cancer treatment.
Following the announcement, Summit shares experienced a important decline, falling by 30%.
What’s next
Summit will continue to monitor the trial data for overall survival benefit, which will be crucial for regulatory submissions and the long-term commercial success of ivonescimab as a cancer immunotherapy.